-
-

 
-
Nov 1 2022
Recent article published in Molecular Oncology with MedRod® implants i...

-


PRICE QUOTE AND TECHNICAL INQUIRIES

Request Information


FOLLOW US

Dihydrotestosterone

For mice and rats in metabolic and prostate cancer xenograft, PDX and syngeneic studies

Dihydrotestosterone (DHT) implants for preclinical in vivo studies.
Drug release: At least 100 days
Dose range: 10 µg – 100 µg/day.

-
About Us
 
-
 Management
-
 History
-
Implant Technology
 
-
 E1
-
 E2
-
 DHT
-
 P4
-
 TE
-
 LTZ
-
Drug Delivery Solutions
 
-
 Feasibility study of novel compound
-
Services
 
References
 
-
 MedRod brochure
-
Contact Us
 
Benefits of MedRod®
 
138413  | Copyright © 2023 PreclinApps Ltd   
Web dev. Webbinen.net